Novo Nordisk
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.About NVO
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments.
NVO Key Statistics
Stock Snapshot
With a market cap of 217.62B, Novo Nordisk(NVO) trades at $48.78. The stock has a price-to-earnings ratio of 14.17 and currently yields dividends of 2.5%.
On 2025-11-27, Novo Nordisk(NVO) stock moved within a range of $46.81 to $49.03. With shares now at $48.78, the stock is trading +4.2% above its intraday low and -0.5% below the session's peak.
Trading activity shows a volume of 17.83M, compared to an average daily volume of 23.47M.
Over the past 52 weeks, Novo Nordisk(NVO) stock has traded between a high of $112.52 and a low of $43.08.
Over the past 52 weeks, Novo Nordisk(NVO) stock has traded between a high of $112.52 and a low of $43.08.
NVO News
The mid-cap biotech could become a notable player in the industry's hottest therapeutic area. Novo Nordisk (NVO +3.51%), a Denmark-based drugmaker, is currentl...
Patients could soon access higher-dose injections. Shares of Novo Nordisk (NVO +3.53%) are gaining on Monday, up 3.5% as of 2:40 p.m. ET. The jump comes as the...
On Wednesday, Novo Nordisk A/S (NYSE:NVO) submitted its supplemental marketing application to the U.S. Food and Drug Administration (FDA) for a higher dose of s...
Analyst ratings
56%
of 32 ratingsMore NVO News
Novo Nordisk (NVO) stock jumped Wednesday, breathing easily on a lighter-than-feared discount for its semaglutide-based products, Ozempic and Wegovy, under the...
The current maximum Wegovy dose approved for use in the U.S. is a 2.4-milligram injection. Hollie Adams/Reuters Novo Nordisk NOVO.B 4.77 %increase; green up po...
The U.S. Centers for Medicare and Medicaid Services (CMS) on Tuesday announced that it has secured lower prices for 15 of its highest‑cost medications, resultin...
The weight loss drug market may approach almost $100 billion by the end of the decade. The words "Ozempic" and "Wegovy" almost have become household names as t...
The Centers for Medicare & Medicaid Services (CMS) announced price cuts across 15 drugs through the Medicare health insurance system, effective in 2027. The Tru...
Novo Nordisk A/S (NYSE:NVO) shouldn't be trading like a meme stock — not when it's sitting on deep-value fundamentals, a GLP-1 fortress, and a pipeline pivot th...
Good news from a GLP-1 receptor agonist clinical trial hit the market today. Another day and another release of results from a clinical trial from Novo Nordisk...
